Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 2516

Special Issue Editors

Dr. Diego Orsini

E-Mail Website
Guest Editor
1. Departmental Faculty of Medicine UniCamillus, Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy
2. Clinical Dermatology Unit, San Gallicano Dermatological Institute–IRCCS, 00144 Rome, Italy
Interests: psoriasis; psoriatic arthritis; atopic dermatitis; eczema; pityriasis versicolor; venereology
Special Issues, Collections and Topics in MDPI journals
Dr. Alessandra Narcisi

E-Mail Website
Guest Editor
1. Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy
Interests: psoriasis; biologics; atopic dermatitis; inflammatory skin diseases; translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite you to contribute to the Special Issue "New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition". The 1st edition is available at https://www.mdpi.com/journal/jcm/special_issues/8XV542TY28. This Special Issue combines original research and review papers with a focus on recent advances in psoriasis and psoriatic arthritis.

Psoriasis and psoriatic arthritis are chronic immune-mediated diseases with increasing global prevalence that significant impact patients' quality of life. As complex systemic inflammatory diseases, their clinical manifestations extend beyond skin lesions and can also affect joints and other organ systems. Recent advances in the treatment of psoriasis and PsA have led to significant progress with a deeper understanding of disease pathogenesis.

This Special Issue highlights cutting-edge research in the field of psoriasis and psoriatic arthritis, focusing on novel treatment strategies, clinical management, comorbidities, and real-world outcomes. It aims to bring together the latest reviews and original articles on psoriasis and PsA, exploring scientific knowledge in this rapidly evolving field and promoting practical communication among clinicians.

Dr. Diego Orsini
Dr. Alessandra Narcisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • inflammatory skin disease
  • inflammatory autoimmune disease
  • immunotherapy
  • autoimmunity
  • comorbidities
  • therapeutic
  • diagnosis
  • treatment
  • management
  • biologics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1936 KB  
Article
Early and Mid-Term Ultrasound Response to Guselkumab in Psoriatic Arthritis: A Real-World Cohort from a Single Tertiary Rheumatology Center
by Filippo Messina, Massimo Caimi, Linda Lucchetti, Marco Bonifacio, Emanuele Fiorino and Alessandro Conforti
J. Clin. Med. 2026, 15(3), 1196; https://doi.org/10.3390/jcm15031196 - 3 Feb 2026
Viewed by 556
Abstract
Objective: To quantify early and mid-term changes in ultrasound-detected synovitis and enthesitis after initiating guselkumab in psoriatic arthritis (PsA) and to contextualize imaging responses alongside clinical outcomes. Methods: We conducted a retrospective single-center cohort study of consecutive CASPAR-classified adults (n = 20) [...] Read more.
Objective: To quantify early and mid-term changes in ultrasound-detected synovitis and enthesitis after initiating guselkumab in psoriatic arthritis (PsA) and to contextualize imaging responses alongside clinical outcomes. Methods: We conducted a retrospective single-center cohort study of consecutive CASPAR-classified adults (n = 20) initiating guselkumab 100 mg (week 0/week 4, then q8w; q4w intensification per routine practice). Power Doppler ultrasound (PDUS) followed EULAR–OMERACT standards at baseline (T0), Month 3 (T3), and Month 6 (T6). The primary endpoint was within-patient change in 24-joint GLOESS. Secondary endpoints included OMERACT entheseal scores (activity-only; activity + structure), DAPSA states, PASI, and 6-month persistence. Within-patient changes were assessed using Wilcoxon signed-rank tests (two-sided). Results: All 20 patients completed T6. GLOESS decreased from T0 to T3 (mean Δ −4.05 ± 2.78; p = 0.0312) and to T6 (mean Δ −5.70 ± 4.05; p = 0.0001). Component summaries showed a numerically larger early decrease in synovial PD signal than in grayscale synovial hypertrophy (descriptive). Enthesitis scores improved: OMERACT activity-only median Δ −2.0 at T3 (p = 0.0313) and −3.5 at T6 (p = 0.016); activity + structure median Δ −1.5 at T3 (p = 0.0412) and −3.0 at T6 (p = 0.031). The estimated structural component (OMERACT-1 minus OMERACT-2) was similar across visits (descriptive), indicating improvements driven predominantly by inflammatory signal suppression rather than detectable changes in structural lesions over 6 months. Among patients with baseline PD-positive enthesitis (n = 7), PD negativity (OMERACT-2 = 0) occurred in 2/7 (28.6%) by T6. Clinical domains (DAPSA, PASI) improved in parallel, and 6-month persistence was high. Conclusions: In routine care, guselkumab was associated with a significant improvement in PD-inclusive ultrasound synovitis scores by 3 months, which deepened by 6 months, alongside an improvement in entheseal activity measures. Over 6 months, entheseal structural burden appeared stable; these findings should be considered hypothesis-generating and warrant confirmation in prospective controlled studies. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition)
►▼ Show Figures

Figure 1

11 pages, 821 KB  
Article
Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study
by Ruggero Cascio Ingurgio, Angela Alfano, Elena Matteodo, Luciano Ibba, Luigi Gargiulo, Giovanni Paolino, Santo Raffaele Mercuri, Andrea Carugno, Nicola Zerbinati, Stefano Bighetti, Antonio Costanzo, Alessandra Narcisi and Mario Valenti
J. Clin. Med. 2026, 15(2), 631; https://doi.org/10.3390/jcm15020631 - 13 Jan 2026
Viewed by 882
Abstract
Background: Psoriasis involving difficult-to-treat anatomical areas, such as the scalp, genitalia, fingernails, and palmoplantar regions, carries a disproportionate disease burden and often requires systemic therapy. In this context, real-life data comparing the long-term effectiveness of tildrakizumab 100 mg versus 200 mg in [...] Read more.
Background: Psoriasis involving difficult-to-treat anatomical areas, such as the scalp, genitalia, fingernails, and palmoplantar regions, carries a disproportionate disease burden and often requires systemic therapy. In this context, real-life data comparing the long-term effectiveness of tildrakizumab 100 mg versus 200 mg in patients with difficult-to-treat psoriasis remain limited. Methods: This multicenter retrospective observational study included adult patients in three Italian dermatology centers. Global efficacy endpoints included PASI75, PASI90, PASI100, and absolute PASI ≤ 2 at weeks 16, 32, 52, and 104. Site-specific effectiveness was assessed as complete clearance (PGA = 0) in patients with baseline involvement (PGA ≥ 2) of difficult-to-treat areas. Outcomes were described by dose. Results: 183 patients were included (100 mg: n = 89; 200 mg: n = 94). Patients receiving 200 mg had higher baseline BMI and were more frequently biologic-experienced. At week 104, PASI75 was achieved by 94.2% of patients receiving 100 mg and 94.7% receiving 200 mg, while PASI90 and PASI100 were achieved by 82.7% vs. 57.9% and 48.1% vs. 47.4%, respectively. Clearance of difficult-to-treat areas improved progressively across all sites. Scalp and genital psoriasis showed higher and earlier clearance rates, whereas nail and palmoplantar psoriasis showed slower and more heterogeneous responses. No consistent dose-dependent advantage emerged, despite less favorable baseline characteristics in the 200 mg group. Conclusions: Over 104 weeks, tildrakizumab showed sustained long-term effectiveness in both global disease control and difficult-to-treat areas. The 200 mg dose, used in a more difficult-to-treat population, achieved comparable long-term outcomes, supporting dose optimization in clinical practice. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition)
►▼ Show Figures

Figure 1

12 pages, 265 KB  
Article
Evaluation of Major Autohemotherapy (MAH) in Psoriasis Patients Using Serum Inflammatory Markers
by Seçil Soylu, Nazlı Şensoy, Nurhan Doğan, Halit Buğra Koca and Tülay Köken
J. Clin. Med. 2026, 15(2), 485; https://doi.org/10.3390/jcm15020485 - 8 Jan 2026
Viewed by 669
Abstract
Background/Objectives: Psoriasis is a chronic, inflammatory, systemic skin disease. Although topical and systemic drugs with proven effectiveness are used in the treatment, ozone therapy is also applied as a treatment option based on clinical personal experience and with limited published knowledge. In [...] Read more.
Background/Objectives: Psoriasis is a chronic, inflammatory, systemic skin disease. Although topical and systemic drugs with proven effectiveness are used in the treatment, ozone therapy is also applied as a treatment option based on clinical personal experience and with limited published knowledge. In this project, the aim was to evaluate the effectiveness of major ozone therapy in psoriasis patients together with biomarkers in serum. Methods: A total of 26 psoriasis patients and 19 healthy controls were included in the study. The disease severity was evaluated by the psoriasis area severity index score and grouped as mild, moderate/severe. Serum tumor necrosis factor alpha (TNF-α), interleukin 1-beta (IL-1β), high-sensitivity C-reactive protein (Hs-CRP), sialic acid, and Sialic acid binding Ig-like Lectin-14 (Siglec-14) levels were investigated in controls and psoriasis patients. Results: Psoriasis area severity index (PASI) score decreased significantly in psoriasis patients after ozone autohemotherapy application (p < 0.005). The values of IL-1β, sialic acid, and Siglec-14 after treatment in healthy subjects were statistically significantly higher than in psoriasis patients. It was found that Hs-CRP and Siglec-14 decreased in all patients after treatment, Hs-CRP decreased more significantly in mild psoriasis patients, and Siglec-14 decreased in both mild and moderate-severe groups (p < 0.05). Conclusions: Our research results suggest that ozone autohemotherapy has clinical efficacy in psoriasis patients, inflammation also has a role in the mechanism of action, and its effectiveness in treatment can be evaluated with inflammation markers. Full article
(This article belongs to the Special Issue New Clinical Advances in Psoriasis and Psoriatic Arthritis: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop